Publication: Aripiprazole for Irritability in Asian Children and Adolescents with Autistic Disorder: A 12-Week, Multinational, Multicenter, Prospective Open-Label Study
2
Issued Date
2018-08-01
Resource Type
ISSN
15578992
10445463
10445463
Other identifier(s)
2-s2.0-85050262357
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Child and Adolescent Psychopharmacology. Vol.28, No.6 (2018), 402-408
Suggested Citation
Hyo Won Kim, Eun Jin Park, Ji Hoon Kim, Vitharon Boon-Yasidhi, Jariya Tarugsa, Alexis Reyes, Stella Manalo, Yoo Sook Joung Aripiprazole for Irritability in Asian Children and Adolescents with Autistic Disorder: A 12-Week, Multinational, Multicenter, Prospective Open-Label Study. Journal of Child and Adolescent Psychopharmacology. Vol.28, No.6 (2018), 402-408. doi:10.1089/cap.2017.0152 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/46492
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Aripiprazole for Irritability in Asian Children and Adolescents with Autistic Disorder: A 12-Week, Multinational, Multicenter, Prospective Open-Label Study
Abstract
© 2018, Mary Ann Liebert, Inc. Objectives: We investigated the effectiveness and tolerability of aripiprazole in the treatment of irritability in Asian children and adolescents (6-17 years) with autistic disorder in a 12-week, multinational, multicenter, open-label study. Methods: Sixty-seven subjects (10.0 ± 3.1 years old, 52 boys) were enrolled and treated with flexibly dosed aripiprazole for 12 weeks (mean dose, 5.1 ± 2.5 mg; range 2-15 mg). Results: Aripiprazole significantly reduced the mean caregiver-rated scores for the Irritability, Lethargy/Social Withdrawal, Stereotypy, Hyperactivity, and Inappropriate Speech subscales of the Aberrant Behavior Checklist from baseline to week 12 (p < 0.001 for all subscales). Clinician-rated Clinical Global Impression Severity of Illness scale score also improved from baseline through week 12 (p < 0.001). The most common adverse event was weight gain and no serious adverse event related to aripiprazole treatment was noted. Conclusion: Our results suggest that aripiprazole is effective and generally tolerable in the treatment of irritability in Asian children and adolescents with autistic disorder. Further studies with larger sample sizes and longer treatment durations are required.